Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform
Tuesday, 23 April 2024 () DRESDEN, Germany & LEXINGTON, Mass.--(BUSINESS WIRE)--Seamless Therapeutics today announced the appointments of Albert Seymour, Ph.D., as its new President and Chief Executive Officer and Adam Rosenberg as Independent Chairman of the companyβs Board of Directors. Both bring longstanding track records of successfully leading trailblazing biotechnology companies with an emphasis on gene editing and novel technologies. In addition, their combined experience will be instrumental in establishing Sea
Tuesday, 23 April 2024 ()
